We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$196M
Cap. Flow
-$299M
Cap. Flow %
-11.74%
Top 10 Hldgs %
37.92%
Holding
126
New
21
Increased
16
Reduced
23
Closed
19

Top Buys

Rank Stock Value
1
ADPT
Adeptus Health Inc
ADPT
+$38.6M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$38M
3
DBVT
DBV Technologies
DBVT
+$30M
4
HUM icon
Humana
HUM
+$28.3M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$67.9M
2
SAGE
Sage Therapeutics
SAGE
+$35.7M
3
MCK icon
McKesson
MCK
+$27.5M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$27.4M
5
AET
Aetna Inc
AET
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Financials 3.21%
3 Industrials 0.75%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
76
DELISTED
Agile Therapeutics
AGRX
$1.9M 0.07%
125
– –
ACUR
77
DELISTED
Acura Pharmaceuticals
ACUR
$1.9M 0.07%
1,025,641
– –
ATEC icon
78
Alphatec Holdings
ATEC
$1.31B
$1.75M 0.07%
415,228
– –
PCRX icon
79
Pacira BioSciences
PCRX
$1.01B
$1.69M 0.07%
+50,000
New +$2.46M
INNL
80
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.67M 0.07%
+302,923
New +$2.48M
MTEM
81
DELISTED
Molecular Templates, Inc.
MTEM
$1.64M 0.06%
+15,656
New +$1.12M
TRIL
82
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.55M 0.06%
172,307
– –
ALDX icon
83
Aldeyra Therapeutics
ALDX
$102M
$1.52M 0.06%
267,764
-203,495
-43% -$1.14M
PRTK
84
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.39M 0.05%
+100,000
New +$1.47M
OCRX
85
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.09M 0.04%
572,893
+497,600
+661% +$1.31M
CYNA
86
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$818K 0.03%
+48,840
New +$657K
EGLT
87
DELISTED
Egalet Corporation
EGLT
$805K 0.03%
162,288
-434,835
-73% -$2.58M
STRM
88
DELISTED
Streamline Health Solutions
STRM
$796K 0.03%
44,198
– –
ENDP
89
DELISTED
Endo International plc
ENDP
$468K 0.02%
+30,000
New +$622K
PACB icon
90
Pacific Biosciences
PACB
$447M
$444K 0.02%
+63,072
New +$576K
TCON
91
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$296K 0.01%
338
-1,647
-83% -$2.18M
CDNA icon
92
CareDx
CDNA
$2.05B
$221K 0.01%
51,204
-177,796
-78% -$823K
RNVA
93
DELISTED
Rennova Health, Inc.
RNVA
$111K ﹤0.01%
392
-395
-50% -$119K
CDTX
94
DELISTED
Cidara Therapeutics
CDTX
– –
-3,439
Closed -$873K
ELV icon
95
Elevance Health
ELV
$80.9B
– –
-102,000
Closed -$14.2M
GSK icon
96
GSK
GSK
$104B
– –
-1,340,308
Closed -$67.9M
MCK icon
97
McKesson
MCK
$98.5B
– –
-175,000
Closed -$27.5M
MGNX icon
98
MacroGenics
MGNX
$285M
– –
-517,920
Closed -$9.71M
NVAX icon
99
Novavax
NVAX
$1.35B
– –
-122,813
Closed -$12.7M
PFE icon
100
Pfizer
PFE
$143B
– –
-26,350
Closed -$741K
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2016 Portfolio in Review

As of Q2 2016, Deerfield Management held 126 positions worth $2.54B, up 8.3% from $2.35B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $299M in Q2 2016, closing 19 positions and reducing 23 holdings. Its most notable exit was GSK, an estimated $67.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in Syros Pharmaceuticals, Inc. Common Stock worth $38M.

  • Deerfield Management's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 209,522 shares worth $38M.
  • Deerfield Management added most to Adeptus Health Inc in Q2 2016, an estimated $38.6M increase.
  • Deerfield Management's biggest Q2 2016 reduction was Aetna Inc, cutting an estimated $25.9M.
  • Deerfield Management fully exited GSK in Q2 2016, selling an estimated $67.9M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2016.
  • Deerfield Management opened 21 new positions and closed 19 in Q2 2016.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.